Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management

A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirsaeidi, Mehdi, Barletta, Pamela, Glassberg, Marilyn K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834642/
https://www.ncbi.nlm.nih.gov/pubmed/31737640
http://dx.doi.org/10.3389/fmed.2019.00248
_version_ 1783466518228500480
author Mirsaeidi, Mehdi
Barletta, Pamela
Glassberg, Marilyn K.
author_facet Mirsaeidi, Mehdi
Barletta, Pamela
Glassberg, Marilyn K.
author_sort Mirsaeidi, Mehdi
collection PubMed
description A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD.
format Online
Article
Text
id pubmed-6834642
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68346422019-11-15 Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management Mirsaeidi, Mehdi Barletta, Pamela Glassberg, Marilyn K. Front Med (Lausanne) Medicine A subgroup of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), characterized by inflammation and progressive scarring of the lungs that can lead to respiratory failure. Although ILD remains the major cause of death in these individuals, there is no consensus statement regarding the classification and characterization of SSc-related ILD (SSc-ILD). Recent clinical trials address the treatment of SSc-ILD and the results may lead to new disease-altering therapies. In this review, we provide an update to the diagnosis, management and treatment of SSc-ILD. Frontiers Media S.A. 2019-10-31 /pmc/articles/PMC6834642/ /pubmed/31737640 http://dx.doi.org/10.3389/fmed.2019.00248 Text en Copyright © 2019 Mirsaeidi, Barletta and Glassberg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Mirsaeidi, Mehdi
Barletta, Pamela
Glassberg, Marilyn K.
Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
title Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
title_full Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
title_fullStr Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
title_full_unstemmed Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
title_short Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
title_sort systemic sclerosis associated interstitial lung disease: new directions in disease management
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834642/
https://www.ncbi.nlm.nih.gov/pubmed/31737640
http://dx.doi.org/10.3389/fmed.2019.00248
work_keys_str_mv AT mirsaeidimehdi systemicsclerosisassociatedinterstitiallungdiseasenewdirectionsindiseasemanagement
AT barlettapamela systemicsclerosisassociatedinterstitiallungdiseasenewdirectionsindiseasemanagement
AT glassbergmarilynk systemicsclerosisassociatedinterstitiallungdiseasenewdirectionsindiseasemanagement

Ejemplares similares